1. New Classes of Therapy in Multiple Myeloma

2. Learning Goals

3. Overall Survival in MM

4. Backbone Agents

5. MM Agents Approved in 2015

6. Continuing Challenges

7. Therapies in Development

8. Targeting the Proteasome

9. TOURMALINE-MM1 Ixazomib + Len/Dex vs Placebo + Len/Dex

10. TOURMALINE-MM1 Efficacy

11. Oprozomib

12. HDAC Inhibitors Targeting the Aggresome Pathway

13. PANORAMA-1 Efficacy

14. PANORAMA-1 Toxicity

15. Future Directions for HDAC Inhibitors

16. Potential mAb Targets

17. Elotuzumab

18. ELOQUENT-2 Len/Dex ± Elotuzumab

19. Len/Dex ± Elotuzumab Additional Insights

20. Daratumumab Potential Mechanisms of Action

21. Daratumumab Monotherapy Phase 2, ≥ 3 Lines of Prior Therapy

22. Daratumumab in Combination

23. Therapies in Development Antibodies

24. Pembrolizumab + Pom/Dex

25. Therapies in Development Novel Targets

26. Conclusions

27. Abbreviations

28. Abbreviations (cont)

29. Abbreviations (cont)